Valuation: LivaNova PLC

Market Cap 4.36B 3.81B 3.53B 3.24B 6.12B 420B 6.23B 42.05B 16.52B 205B 16.38B 16.02B 709B P/E 2026 *
28.5x
P/E 2027 * 24.7x
Enterprise Value 4.38B 3.83B 3.54B 3.25B 6.16B 422B 6.26B 42.27B 16.6B 206B 16.47B 16.1B 712B EV / Sales 2026 *
2.91x
EV / Sales 2027 * 2.6x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2024-02-29
Director of Finance/CFO 56 2020-10-30
Investor Relations Contact - 2022-07-31
Director TitleAgeSince
Director/Board Member 69 2015-10-18
Chairman 74 2021-06-08
Director/Board Member 62 2019-06-17
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.64% - - 4.36B
+10.71%+4.69%-24.98%-7.64% 155B
+3.84%+1.42%-6.93%-3.63% 103B
+3.85%+1.83%+3.41%+60.29% 57.7B
-1.11%+4.77%+38.09%+52.37% 52.27B
+3.26%+6.02%-10.29%-37.68% 42.68B
+4.23%+0.64% - - 33.35B
+7.22%+6.79%-7.31%-43.27% 28.06B
+0.96%+1.34%+61.53%-5.52% 25.36B
-0.85%+8.07%-4.63%-18.66% 21.03B
Average +3.18%+0.23%+6.11%-0.47% 57.66B
Weighted average by Cap. +5.11%-1.71%-3.28%+2.68%

Financials

2026 *2027 *
Net sales 1.51B 1.32B 1.22B 1.12B 2.12B 145B 2.15B 14.54B 5.71B 70.96B 5.66B 5.54B 245B 1.61B 1.41B 1.3B 1.2B 2.27B 156B 2.31B 15.56B 6.11B 75.96B 6.06B 5.93B 262B
Net income 148M 130M 120M 110M 208M 14.3B 212M 1.43B 562M 6.98B 557M 545M 24.11B 179M 157M 145M 133M 252M 17.29B 256M 1.73B 680M 8.44B 674M 659M 29.15B
Net Debt 22.09M 19.31M 17.86M 16.39M 31.01M 2.13B 31.55M 213M 83.66M 1.04B 82.96M 81.13M 3.59B -165M -144M -133M -122M -231M -15.85B -235M -1.59B -623M -7.74B -618M -604M -26.73B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA